Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179751
Status:
TERMINATED
Last Update Posted:
2005-11-07
First Post:
2005-09-10
Brief Title:
A Phase III Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
Sponsor:
Celgene Corporation
Organization:
Celgene
Study Overview
Official Title:
A Phase III Study Of Lenalidomide Revlimid In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas
Status:
TERMINATED
Status Verified Date:
2005-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1 8 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in subjects with advanced pancreatic carcinoma Subjects will receive oral lenalidomide days 1-21 and weekly gemcitabine days 1 8 15 in 28 day cycles until documented disease progression occurs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None